Panel Schedule « European Biotech Investor Day 2020

Event Panel Schedule

Thu, 25 Jun 2020

	TBA
Webcast	Keynote by Ben Thorpe - Head of Healthcare Banking Europe - Goldman Sachs Ben Thorpe , Head of European Healthcare Investment Banking / Goldman Sachs & Co. Ben is a Partner managing director in the Healthcare Investment Banking Team, which he joined in 1999. He has a degree form University of Durham.
Webcast	Morning Panel - What it Takes: A Successful IPO in the New Virtual World Jennifer Porcelli , Senior Vice President / Solebury Trout Jennifer Porcelli joined the Trout Group in March of 2015. Prior to joining Trout, Jen worked at UBS Investment Bank on the Corporate Access team, where she spent over 11 years working with companies across the Energy & Utilities, Media… Jennifer Porcelli joined the Trout Group in March of 2015. Prior to joining Trout, Jen worked at UBS Investment Bank on the Corporate Access team, where she spent over 11 years working with companies across the Energy & Utilities, Media & Telecom, and Basic Materials sectors. Prior to joining the Corporate Access team, Jen worked on the UBS Healthcare Investment Banking team, primarily focused on developing internal & external communications. Jen started her career at JPMorgan, working on the Marketing & Communications team. Jen graduated from Georgetown University with a Bachelor of Science degree in Marketing & Communications, with a Minor in Psychology. While at Georgetown, Jen had the opportunity to work on Capitol Hill for two years, serving as an intern for Senator Tim Johnson. She also served as the Business Editor of The Georgetown Voice. Jen holds Series 7, 79, and 63 securities licenses. She enjoys running, practicing yoga, and spending time with family. Elise Wang , Principal / Deerfield Management Company Elise Wang is a Principal on the Public Structured Finance group at Deerfield and joined the Firm in 2010. Ms. Wang provides extensive research and analysis on individual companies operating in the healthcare industry in both the US and Europe. Prior… Elise Wang is a Principal on the Public Structured Finance group at Deerfield and joined the Firm in 2010. Ms. Wang provides extensive research and analysis on individual companies operating in the healthcare industry in both the US and Europe. Prior to Deerfield, Ms. Wang was a Senior Research Analyst and Managing Director at PaineWebber and Citigroup. She began her career in healthcare as a venture capitalist and banker at PaineWebber and was an officer of PaineWebber Development Corporation, which managed nearly $1 billion in assets representing three PaineWebber funds and several research and development limited partnerships (RDLPs) invested in biotechnology and high technology companies. Ms. Wang holds an A.B. in Engineering Sciences with a specialty in Biomechanics from Harvard University and an M.B.A. from Harvard Business School. Robert Puopolo , Partner / Goodwin Procter LLP Rob Puopolo, a partner in Goodwin’s Life Sciences practice, focuses his practice on representing public and privately held life sciences companies, as well as the venture capital firms, hedge funds and investment banks that focus on these companies. Rob Puopolo, a partner in Goodwin’s Life Sciences practice, focuses his practice on representing public and privately held life sciences companies, as well as the venture capital firms, hedge funds and investment banks that focus on these companies. Reinhard Kandera , CFO / Hookipa Pharma Reinhard Kandera joined Hookipa as CFO in April 2017. Prior to that he was Chief Financial Officer of Valneva. He has been with Intercell since 2001, in charge of leading the company’s Finance and Investor relation functions and processes and was… Reinhard Kandera joined Hookipa as CFO in April 2017. Prior to that he was Chief Financial Officer of Valneva. He has been with Intercell since 2001, in charge of leading the company’s Finance and Investor relation functions and processes and was appointed as member of the Management Board and CFO in 2009. Before joining Intercell he was with Deutsche Bank. He is a financial expert with experience in corporate and investment banking and has broad industry know-how. Reinhard Kandera holds doctorate degrees in both, law and finance. Gil Bar-Nahum , Managing Director / Jefferies LLC Dr. Gil Bar-Nahum is a Managing Director in the Global Healthcare Investment Banking Group and leads the International Biotechnology effort at Jefferies. Dr. Bar-Nahum has over 17 years of experience and was an Executive Director in UBS Investment… Dr. Gil Bar-Nahum is a Managing Director in the Global Healthcare Investment Banking Group and leads the International Biotechnology effort at Jefferies. Dr. Bar-Nahum has over 17 years of experience and was an Executive Director in UBS Investment Bank's Global Healthcare Group until 2009. Prior to that, Dr. Bar-Nahum worked as a Biotechnology Research Analyst for UBS where he served as an Associate Director covering companies in the Life Sciences space. Dr. Bar-Nahum has executed and advised on over 100 transactions in the life sciences space, with particular expertise in Biotechnology Mergers and Acquisitions, and in raising capital for highly innovative developmental stage growth companies. In the last several years, Dr. Bar-Nahum has led follow-on financings and Initial Public offerings of numerous international Biotechnology Companies, including 10 foreign private issuers onto NASDAQ, raising north of $2bn in proceeds. Dr. Bar-Nahum received his PhD in biochemistry from the Sackler Institute at the New York University School of Medicine. The subject of Dr. Bar-Nahum's doctorate work was published twice in the journal Cell. Dr. Bar- Nahum also received an MS from New York University Jordan Saxe , Head of Healthcare / Nasdaq Jordan B. Saxe is Senior Managing Director, Americas in the Global Corporate Client Group at Nasdaq (Nasdaq: NDAQ), the world’s largest exchange. In this role, Mr. Saxe is responsible for leading business development efforts in listings across all… Jordan B. Saxe is Senior Managing Director, Americas in the Global Corporate Client Group at Nasdaq (Nasdaq: NDAQ), the world’s largest exchange. In this role, Mr. Saxe is responsible for leading business development efforts in listings across all sectors. He brings over fifteen years of experience within the exchange field, to bear on his work in guiding companies and their legal financial advisors on the process of listing on the U.S.’s largest electronic market. His focus on working with early stage companies to maximize the financing and visibility opportunities that can be provided by public capital markets means he also works very closely with venture capital, private equity and investment firms to educate them on the liquidity options Nasdaq can provide. His background is in investment research and capital markets. Mr. Saxe works with companies by providing value-added consultative services. He analyzes and interprets market transaction and performance data, and educates companies on the benefits of Nasdaq. Mr. Saxe completed his Bachelor of Science in Business Admin from the University of Vermont.
Webcast	Afternoon Webinar with back to back quick Talks Michael H. Bison , Partner / Goodwin Procter LLP Michael Bison is a partner in Goodwin’s nationally and internationally recognized Technology and Life Sciences practice group and a member of its Life Sciences and Capital Markets practices. He represents privately held and publicly traded companies… Michael Bison is a partner in Goodwin’s nationally and internationally recognized Technology and Life Sciences practice group and a member of its Life Sciences and Capital Markets practices. He represents privately held and publicly traded companies with a strong emphasis on companies across the spectrum of the life sciences industry, including biotechnology, medical devices, diagnostics and healthcare information technology. Mr. Bison also regularly represents leading venture capital firms focused on the life sciences industry in connection with their portfolio company investments, exits and secondary stock sale transactions, as well as underwriters focused on the life sciences industry in connection with capital market and M&A transactions. Mr. Bison typically serves as outside general counsel to his clients, closely advising management teams and boards of directors on a wide variety of matters throughout the company’s life cycle, including company formation and founder issues, venture capital and growth equity financings, public offerings, M&A, strategic collaborations, commercial transactions, corporate governance and general corporate matters. He is regularly recognized by his clients for his extensive industry knowledge and for providing practical, result-oriented legal advice. Mr. Bison has advised numerous international companies with respect to their U.S. listings, capital markets transactions, strategic collaborations and M&A transactions, as well as with respect to the establishment of U.S. subsidiaries and various operational matters with respect to these subsidiaries. Mr. Bison’s work has been recognized by several industry publications, including the Best Lawyers in America, LMG Life Sciences, Who's Who Legal, The Legal 500, Law & Politics magazine, and Boston magazine. Joseph Oakenfold , Vice President / Deutsche Bank AG Joe Oakenfold is the lead salesperson for Deutsche Banks‘ Depositary Receipts business in Europe bringing corporate issuers to the US capital markets and enabling access to the worlds’ largest pool of investment. With over 20 years’ experience, Joe… Joe Oakenfold is the lead salesperson for Deutsche Banks‘ Depositary Receipts business in Europe bringing corporate issuers to the US capital markets and enabling access to the worlds’ largest pool of investment. With over 20 years’ experience, Joe has covered Depositary Receipt roles from Investor Relations and Trading to Product Management and Corporate Sales. Joe has lived and worked in Europe and Asia but also assisted corporates from Latin America, Central and Eastern Europe and the Middle East and Africa to list on US and European exchanges. In the Life Sciences, MedTech and Pharma space, Joe has helped a host of clients including Philips, Smith&Nephew, Chi-Med, Daiichi-Sankyo, Genmab, Ipsen, Lundbeck, TiGenix and Bavarian Nordic access US investors through the Deutsche Bank Depositary Receipt platform. Joe is a member of the UK IR society with a Certificate in Investor Relations and Securities Institute qualifications. His career CV includes Deutsche Bank, BNY Mellon, Macquarie and RBC. Patrick Hughes , Director / Nasdaq Patrick has over 15 years of experience working with IR teams in various advisory capacities. Prior to joining Nasdaq, he held financial communication roles at Citigate Dewe Rogerson and at Burson-Marsteller. Jenny Harper , Partner / PricewaterhouseCoopers I am a Capital Markets & Accounting Advisory partner at PwC with over 20 years of experience on US IPOs, cross-border M&A, and private or public US debt/equity offerings, where I advise companies on transaction readiness, the listing process… I am a Capital Markets & Accounting Advisory partner at PwC with over 20 years of experience on US IPOs, cross-border M&A, and private or public US debt/equity offerings, where I advise companies on transaction readiness, the listing process, navigating SEC regulation, due diligence and transaction related accounting and reporting matters such as IFRS/US GAAP conversions, pro forma information, carve-out financial statements, and SEC comment letters. Based in London for over 15 years, I work with a mix of public and private companies across a variety of industries and have advised on a number of recent or ongoing cross-border M&A deals and US IPOs involving UK and European companies.